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Abstract Both pathogen- and tissue damage-associated molecular patterns induce inflammation 
through toll-like receptors (TLRs), while sialic acid-binding immunoglobulin superfamily lectin receptors 
(Siglecs) provide negative regulation. Here we report extensive and direct interactions between 
these pattern recognition receptors. The promiscuous TLR binders were human SIGLEC-5/9 and 
mouse Siglec-3/E/F. Mouse Siglec-G did not show appreciable binding to any TLRs tested. 
Correspondingly, Siglece deletion enhanced dendritic cell responses to all microbial TLR ligands 
tested, while Siglecg deletion did not affect the responses to these ligands. TLR4 activation triggers 
Neu1 translocation to cell surface to disrupt TLR4:Siglec-E interaction. Conversely, sialidase inhibitor 
Neu5Gc2en prevented TLR4 ligand-induced disruption of TLR4:Siglec E/F interactions. Absence of 
Neu1 in hematopoietic cells or systematic treatment with sialidase inhibitor Neu5Gc2en protected 
mice against endotoxemia. Our data raised an intriguing possibility of a broad repression of TLR 
function by Siglecs and a sialidase-mediated de-repression that allows positive feedback of TLR 
activation during infection.
DOI: 10.7554/eLife.04066.001
Introduction
Nearly 25 years ago, Janeway proposed that the innate immune system discriminates infectious 
nonself from non-infectious self through non-clonally distributed pattern recognition receptors (PRRs) 
(Janeway, 1989, 1992). This concept was supported by the observations of microbial induction of 
costimulatory activity on antigen-presenting cells (Liu and Janeway, 1991, 1992; Wu and Liu, 1994) 
and bolstered as a major pillar in immunology by the identification of TLRs (Medzhitov et al., 1997) 
and its ligands (Poltorak et al., 1998). Over the following decades, TLRs have emerged as a family of 
PRRs that sense a variety of pathogen-associated molecular patterns (PAMPs), ranging from microbial 
glycan, bacterial glycolipids, flagellin, and viral and bacterial nucleic acids (Kawai and Akira, 2010).
Surprisingly, accumulating data demonstrated that TLRs also sense cellular components released 
after cellular injuries, such as heat-shock proteins (Millar et al., 2003), HMGB1 (Apetoh et al., 
2007; Ivanov et al., 2007; Tian et al., 2007) and S100 (Hiratsuka et al., 2008; Tsai et al., 2014). 
These components were collectively called DAMPs for danger-associated molecular patterns, 
based on Matzinger's ‘danger theory’ (Matzinger, 1994). In addition to TLRs, Nod-like receptors 
(NLRs) have also been shown to respond to both microbial components (Franchi et al., 2012) and 
cellular injuries (Ting et al., 2008; Tschopp and Schroder, 2010). Since these PRRs respond to 
both infectious and noninfectious inflammatory stimuli, additional regulatory mechanism was deemed 
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needed if pattern recognition receptors were to be the key components to discriminate the two 
(Liu et al., 2009).
We have reported that CD24-Siglec-G/10 interactions selectively inhibit host responses to DAMPs 
without affecting responses to PAMPs (Chen et al., 2009). These data suggest a new mechanism for 
limiting inflammation to autologous molecules, and a framework for integrating the self-nonself and 
danger theories of immunity (Liu et al., 2009).
Siglecs are membrane-bound lectins that constitute the sialic acid-binding immunoglobulin super 
family with distinct cellular distribution and glycan specificities (Crocker et al., 2007). Most Siglecs 
have intracellular domains capable of inhibitory signaling. With a few notable exceptions (Stamenkovic 
et al., 1991; Chen et al., 2009; Bandala-Sanchez et al., 2013; McMillan et al., 2013), the natural 
ligands for most Siglecs remain to be determined. The selective effect of Siglec-G in regulating host 
response to DAMPs raised two interesting questions: First, do all Siglecs perform similar functions in 
discriminating self from non-self in innate immunity? Second, do Siglec family members directly interact 
with other families of pattern recognition receptors and play a broad function in regulating innate 
immunity? Here we addressed these two issues by revealing a broad and direct interaction between 
TLRs and many Siglecs, and by highlighting Siglec-G for its lack of direct interactions with TLR.
A standard test to validate Siglec-mediated interactions is to measure their susceptibility to sial-
idase treatment (Crocker et al., 2007). The implication of this cardinal feature in immune recognition 
has not been widely explored. Our previous studies have demonstrated that CD24-Siglec-G interac-
tions are disrupted by bacterial sialidase and that such disruptions exacerbates sepsis (Chen et al., 
2011). Since most pathogens do not express sialidases, the implication of this observation on immune 
eLife digest Many living things have an immune system that is able to detect invading bacteria, 
viruses and other pathogens and trigger a response targeted against the threat before it causes 
lasting damage. Cells employ a number of different receptors that can detect these pathogens or 
the molecules that they produce.
In animals, toll-like receptors (or TLRs) are a type of protein that recognizes patterns or structures 
that are found in many different types of pathogen, known as pathogen-associated molecular 
patterns (or PAMPs). Injured cells release proteins that are also recognized by toll-like receptors and 
are called danger associated molecular patterns (or DAMPs). An immune response is triggered when 
PAMPs and DAMPs are recognized, but the response must be properly controlled. If it goes awry, 
it can result in an over-activation of the immune cells that can lead to life-threatening conditions, 
one of which is called sepsis.
Siglecs are proteins that bind to a sugar molecule, which is found attached to many other proteins, 
and are known to inhibit the immune response. However, it remained unclear how Siglecs do this 
and if they can interact directly with toll-like receptors. Chen et al. now show that most (although 
not all) Siglecs bind to TLRs, and that deleting the gene for a Siglec protein that can bind to multiple 
TLRs boosted the response of the immune cells to a range of microbial PAMPs. Deleting the gene 
for another Siglec that did not bind to any TLRs had no effect on the immune response.
Chen et al. suggest that the Siglec proteins that interact with toll-like receptors act a bit like a 
brake that slows down the activation of the receptors. However, when an immune cell detects a 
foreign molecule through a TLR, an enzyme called Neu1 is relocated from the inside of the cell to 
the cell's surface, where it removes the sugar molecules from the TLRs. This disrupts the interaction 
between the TLRs and the Siglecs, thus activating the receptors and triggering an immune response 
against the invading pathogen or damaged cells. This represents a newly discovered mechanism 
that can regulate the signaling of TLRs.
Chen et al. also show that a chemical compound that stops the function of the Neu1 enzyme 
prevents the toll-like receptors—and hence the immune cells—from becoming overly activated. 
Mice treated with this compound are protected against sepsis triggered by the presence of a 
bacterial PAMP. These results suggest that the Neu1 enzyme may be a promising new target for 
treating sepsis; further work will now be required to assess the potential side effects caused by 
inhibiting this enzyme.
DOI: 10.7554/eLife.04066.002
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regulation during infection and autoimmune diseases is less clear. On the other hand, mammals 
express at least four sialidases, Neu1-4 (Miyagi and Yamaguchi, 2012). Several studies have sug-
gested that activation of TLR can be attenuated by sialidase inhibitors (Amith et al., 2010; Abdulkhalek 
et al., 2011). Both Neu1 and Neu3 have been suggested as targets of the inhibitors (Amith et al., 
2010; Abdulkhalek et al., 2011). Neu1 has been shown to cause TLR4 dimerization, which was 
suggested to be important for its regulation of TLR4 activation (Amith et al., 2010). Here we report a 
critical role for Neu1 in regulating Siglec-TLR interaction and endotoxemia. Together, our data reveal 
an overlooked network of interactions among Siglecs, host sialidases and TLRs and, with more potent 
Neu1 inhibitors, propose host sialidases as therapeutic targets for lethal endotoxemia.
Results
Extensive Siglec-TLR interactions negative regulate the function of 
multiple TLRs
To test whether TLRs directly interact with Siglecs, we first tested a panel of recombinant human 
SIGLEC fusion proteins for their interaction with human TLRs synthesized by the THP1 cell line using a 
sandwich capture assay. Plates were coated with recombinant SIGLEC-Fc fusion proteins or control 
human Fc. Lysates from the human myeloid cell line THP1 was used as the source of cellular TLRs, as 
this line expresses transcripts of all TLRs at significant levels (Figure 1A). SIGLEC-Fc-bound TLRs were 
detected with anti-TLR antibodies. This assay revealed extensive interaction between the two families 
of pattern recognition receptors (Figure 1B). Among them, Siglec 5 and 9 cross-reacted with virtually 
all TLR tested. In contrast, very little interaction was observed between TLRs and SIGLECS-1, 2, 7, 
10 and 11.
Since the anti-TLR antibodies used also cross-react with their mouse homologs, we carried out 
a similar analysis between mouse Siglecs and Tlrs. As shown in Figure 1C, Siglec-3, E, F and H were 
broadly cross-reactive, while Siglec-G displayed no interaction with any murine Tlr. We validated the 
interaction between Siglec-E and Tlr4 using both pull down and bi-directional immunoprecipitation 
assays. Siglec-E-Fc, but not control IgG, pulled down Tlr4 in the spleen cell lysates (Figure 1D). Anti-
Siglec-E monoclonal antibodies co-precipitated Tlr4, while anti-Tlr4 co-precipitated Siglec-E (Figure 1E). 
To determine whether Siglecs directly interact with TLR, we coated the 96-well plates with recombi-
nant Siglecs or control IgG. After blocking with bovine serum albumin, recombinant TLR4 extracellular 
domain was added, and the bound TLR4 were determined using biotinylated anti-TLR4 and horse-
radish peroxidase-conjugated streptavidin. The data revealed that TLR4 directly interact strongly with 
SIGLEC-5, 6, 9, 11 and modestly with SIGLEC-7 (Figure 1F). In contrast, no interaction was observed 
between SIGLEC-1, 2, 3, 10 and TLR4. Likewise, mouse Siglec-E and F bound strongly to TLR4, 
with Siglec-3 and H showing modest binding to TLR4, and no binding to TLR4 and Siglec-1, 2 and 
G (Figure 1G). Comparisons between Figure 1A,E, and between Figure 1C,G, show that, with the 
modest exception of Siglec-7, recombinant TLR4 recapitulated the specificity of endogenous TLR4. 
Taken together, data in Figure 1 demonstrate broad and direct interaction between TLR and Siglec 
families of PRRs.
Since Siglec-E contains intracellular immunoreceptor tyrosine inhibitory motif (ITIM) and ITIM-like 
domains and associates with molecules known to negatively regulate production of inflammatory 
cytokines, we compared bone marrow-derived dendritic cells (DC) from WT and Siglece−/− mice for 
their responses to prototypic TLR ligands. After overnight stimulation with TLR ligands, we analyzed 
the production of IL-6 and TNFα by DC. As shown in Figure 2A, Siglece−/− DC were 1000-fold more 
responsive to LPS stimulation than Siglece+/+ DC. Likewise, Siglece−/− DC produced at least 10-fold 
more cytokines in response to CpG (Figure 2B). Given the multiple interactions of Siglec-E with other 
TLR (Figure 1C), we tested if endogenous Siglec-E negatively regulates production of inflammatory 
cytokines to other TLR ligands. As shown in Figure 2C, in addition to an enhanced response to TLR4 
and TLR9 ligands, Siglece−/− DC also produced significantly more IL-6 in response to synthetic tri-
acylated lipoprotein Pam3CSK4 (TLR1/2 agonist), heat-killed Listeria monocytogenes (HKLM, Tlr2 
agonist), poly(I:C), (TLR3 agonist), Salmonella typhimurium flagellin (ST-FLA, TLR5 agonist), synthetic 
lipoprotein derived from Mycoplasma salivarium (FSL-1, TLR2/6 agonist) and ssRNA40, a 20-mer phos-
phorothioate-protected single-stranded RNA oligonucleotide containing a GU-rich sequence (TLR8 
agonist). Since Siglec-E negatively regulates responses to all TLR ligands tested, we suggest that the 
physical interactions between Siglec-E and TLRs are biologically significant. Except for a modest elevated 
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response to ssRNA40, Siglecg−/− and Siglecg+/+ DC exhibited similar responses to all TLR ligands tested 
(Figure 2C). This, along with data from our previous report indicating that Siglec-G does not inhibit 
inflammatory response to LPS and poly(I:C), (Chen et al., 2009), is consistent with the lack of physical 
interactions between Siglec-G and TLRs (Figure 1C,G).
The TLR4-Siglec-E interaction is negatively regulated by Neu1
We next tested the impact of LPS stimulation on Siglec-E-TLR4 interaction. As shown in Figure 3A, 
co-precipitation between endogenous TLR4 and Siglec-E was substantially reduced after LPS stim-
ulation. These data demonstrate a dynamic regulation of TLR4-Siglec-E association on DC. Since 
interaction of Siglecs with their ligands is dependent on sialic acid and can be disrupted by siali-
dase (Crocker et al., 2007), and since LPS is devoid of sialidase activity, we evaluated the contribution 
Figure 1. Extensive direct interactions between Siglecs and TLRs. (A) Evaluation of TLR expression using TLR-primer set. Data shown are means and 
SEM of triplicate % of GAPDH levels. (B) and (C) Interactions between human (B) or mouse (C) SIGLEC-Fc fusion proteins and TLRs from THP-1 cells 
(B) or murine splenocyte lysates (C). Recombinant SIGLEC-Fc or control IgG Fc were coated on 96 well plates to capture TLR in the cell lysates. The 
associated TLRs were detected with biotinylated anti-TLR antibodies that cross-react with both mouse and human TLR. Data shown are the log2 ratios 
between Siglec-Fc and IgG Fc in triplicate and were repeated three times. (D) Recombinant Siglec-E binds to endogenous Tlr4. Lysates from C57BL/6 
mouse splenocytes were incubated with either Fc control or SIglec E-Fc. After precipitation with protein A beads, the precipitates were analyzed by 
Western blot, using antibodies against Siglec-E, Tlr4, and Fc. (E) Interaction between endogenous Tlr4 and Siglec-E in D2SC dendritic cells. Lysates from 
D2SC cells were immunoprecipitated with either anti-Siglec-E (top) or Tlr4 (bottom) antibodies. The precipitates were analyzed by Western blot, using 
antibodies against Siglec-E or Tlr4. Similar results were obtained when performed with WT mouse splenocyte lysates (data not shown). (F) Direct 
interaction between human Siglecs and ectodomain of TLR4. As in (A), except the cell lysates were replaced with recombinant TLR4. (G) Direct interaction 
between mouse Siglecs and ectodomain of TLR4. As in (B), except the cell lysates were replaced with recombinant TLR4. Data presented in this figure 
have been reproduced at least three times.
DOI: 10.7554/eLife.04066.003
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of endogenous sialidase, using the D2SC DC cell line (Bachmann et al., 1996). Real-time PCR 
analysis indicated that D2SC cells express Neu1 and to a lesser extent Neu3, but not Neu2  
or Neu4 (Figure 3B). Since TLR4 is a cell surface glycoprotein while Neu1 is primarily lysosomal, 
we evaluated whether Neu1 translocates to the cell surface following LPS stimulation. Fluorescent 
microscopy revealed a robust translocation of Neu1 to cell surface where it co-localized with 
TLR4 (Figure 3C), which is similar to a previous report on macrophages (Liang et al., 2006). 
Flow cytometry confirmed a time-dependent translocation of Neu1 between 6–18 hr following 
LPS stimulation (Figure 3D). To test if Neu1 and TLR4 interact with each other, live cells were 
cross-linked with dithiobis[succinimidyl propionate ] (DSP) to stabilize transient enzyme–substrate 
interactions. After cross-linking, the LPS-treated and untreated D2SC cells were lysed for co-
immunoprecipitation. As shown in Figure 3E, a specific Neu1-TLR4 association was observed only 
after LPS stimulation.
To determine if Neu1 regulates cell surface Siglec-E ligand levels, we compared binding of 
Siglec-E-Fc to either scrambled or Neu1 shRNA-transduced D2SC cells. As shown in Figure 3F, 
silencing of Neu1 increased binding of Siglec-E-Fc to DC. To determine whether Neu1 contributes 
to LPS-induced disassociation between Siglec-E and TLR4, we tested the impact of Neu1 silencing 
on Siglec-E-TLR4 interaction, as measured by co-immunoprecipitation. As a control, we also tested 
the impact of silencing Neu3, which is a constitutive cell surface sialidase. As shown in Figure 3G, 
shRNA silencing of Neu1 abrogated the LPS-induced disassociation of Siglec-E-TLR4 complexes. 
In contrast, shRNA silencing of Neu3 had no effect on Siglec-E-TLR4 interaction.
To determine whether Neu1 regulates production of inflammatory cytokines, we tested three 
independent Neu1 shRNAs (Neu1sh1-3)-silenced D2SC cell lines for their responses to LPS. 
As shown in Figure 3H, the three shRNAs reduced cell surface Neu1 in LPS-stimulated D2SC cells 
with different efficiencies: Neu1 was completely silenced by Sh1 and Sh2, while only partially sup-
pressed by Sh3. Corresponding with the silencing efficiencies, LPS-induced cytokine production 
was more significantly reduced by Sh1 and Sh2 than by Sh3, which had partial effect when com-
pared to scramble control (Figure 3I). Taken together, the data presented in this section demon-
strate dynamic regulation of the TLR-Siglec-E interaction by Neu1 and its impact on DC response 
to LPS, the prototypic TLR4 ligand.
Figure 2. Siglec-E negatively regulates production of inflammatory cytokines by DC in response to TLR ligands. (A) and (B) Siglec-E inhibits production 
of IL-6 and TNFα by bone marrow derived DC. DC cultured from WT or Siglece−/− bone marrow were stimulated with indicated concentrations of LPS (A), 
or poly(I:C) (B) for 16 hr, and supernatant cytokine concentrations were analyzed with cytokine bead array. (C). Targeted mutation of Siglec-E, but not 
Siglec-G, enhances production of IL-6 to multiple TLR ligands. The TLR agonists used are: synthetic triacylated lipoprotein Pam3CSK4 (TLR1/2 agonist), 
heat-killed Listeria monocytogenes (HKLM, Tlr2 agonist), poly(I:C), (TLR3 agonist), Salmonella typhimurium flagellin (ST-FLA, TLR5 agonist), synthetic 
lipoprotein derived from Mycoplasma salivarium (FSL-1, TLR2/6 agonist) and ssRNA40, a 20-mer phosphorothioate-protected single-stranded RNA 
oligonucleotide containing a GU-rich sequence (TLR8 agonist). All agonist were used at 100 ng/ml. Data represent the mean ± SD for three independent 
cultures of DCs in each genotype and were repeated at least three times.
DOI: 10.7554/eLife.04066.004
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Neu1 deletion in hematopoietic cells confers resistance to endotoxemia
To confirm the impact of LPS stimulation on Neu1 translocation and sialylation of primary leukocytes, 
we injected intraperitoneally (i.p.) sublethal doses of LPS (200 μg/mouse) or PBS control into C57BL/6 
mice, and analyzed spleen cells 16 hr later for cell surface expression of Neu1. As shown in Figure 4A, 
LPS stimulation led to upregulation of cell surface Neu1 on DCs, macrophages, and neutrophils. 
Figure 3. A critical role for Neu1 in Tlr4 activation. (A) Siglec-E-Tlr4 association is disrupted by LPS stimulation. D2SC cells were cultured in the presence 
or absence of LPS overnight. Immunoprecipitation was used to test Siglec-E-Tlr4 association as detailed in the Figure 1D legend. (B) Expression 
of Neu1-4 mRNA in D2SC dendritic cells was determined by RT-PCR. Data shown are mean ± SD transcript levels, expressed as % of the housekeeping 
gene HPRT. (C) Translocation of Neu1 and its co-localization with TLR4 in D2SC cells. D2SC were cultured in the presence or absence of LPS (100 ng/ml) 
for 18 hr and co-stained with anti-TLR4 and anti-Neu1 antibodies. (D) Increased cell surface expression of Neu1 on D2SC cells after stimulation with LPS 
as revealed by flow cytometry. D2SC cells were treated with LPS (100 ng/ml) or vehicle for 6 hr (upper panel) or 18 hr (lower panel). The expression of 
cell-surface Neu1 was determined by FACS. (E) Physical association between Neu1 and TLR4. D2SC 2 cell lines were stimulated with 2 μg/ml LPS 
or vehicle for 16 hr were crossed linked with 1 mM DSP at room temperature for 30 min. The lysates were immunoprecipitated with anti-Neu1 and then 
probed with anti-Neu1 or anti-TLR4. (F) Silencing Neu1 by lentivirus shRNA increased the cell surface Siglec-E ligands. Histograms shown on top panels 
are FACS profiles. The bar graphs in the bottom panels represent geometric means ± SD of fluorescence intensity (n = 3). (G) Neu1 disrupts Tlr4-Siglec-E 
association in DC. D2SC dendritic cells were transduced with lentiviral vector carrying scrambled shRNA, three independent Neu1 shRNAs or Neu3 
shRNA. After LPS stimulation for 24 hr, the lysates were used for immunoprecipitation. (H) ShRNA silencing of Neu1 affect cell surface Neu1 levels. Data 
shown are histogram of flow cytometry data depicting cell surface expression of Neu1 in LPS-stimulated D2SC clones. (I) An essential role for Neu1 in 
production of TNFα by D2SC cells. Aliquots of 2 × 105 D2SC transfectants were stimulated with LPS (100 ng/ml) for 12 hr. The culture supernatants were 
subsequently collected and analyzed for TNF-α. Scramble, Neu1sh1, 2, 3 represent stable clones expressing three independent Neu1 ShRNAs. Experiments 
depicted in this figure have been reproduced two to three times.
DOI: 10.7554/eLife.04066.005
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Figure 4. A critical role for hematopoietic cell-expressed Neu1 in endotoxic shock. (A) LPS stimulation in vivo increased cell surface Neu1 on DC, 
macrophage, and neutrophil. Data are representative of those from two independent experiments involving two mice per group. Splenocytes 
were collected from mice 16 hr after they received an injection of LPS (i. p. 200 μg/mouse). (B) The cell surface Siglec-E ligands are down-regulated 
on DC following LPS stimulation. Data shown are means ± SD (n = 3) and have been reproduced twice. (C–H) Lethally irradiated CD45.1 congenic 
B6 mice were transplanted with WT or Neu1−/− BM (5 × 106 cells/mouse). 21 weeks later, the mice were bled to analyze hematopoiesis. (C) Comparable 
reconstitution of donor-derived hematopoietic cells, based on the frequencies of donor-derived CD45.2+ cells. (n = 5). (D) Normal CD45.2+ 
leukocyte composition of PBL as determined by flow cytometry. Populations were defined as: B cells, B220+; monocytes, NK1.1−CD11b+; CD4+  
T cells, CD4+CD3+; CD8+ T cells, CD3+CD8+; NK cells, NK1.1+. (E) Increase of α2,3 and α2,6 sialylation and Siglec-E ligand on Neu1−/− DC. (Gated 
CD11c+ as DCs). Splenocytes from Neu1+/+ and Neu1−/− mice were stained with FITC-conjugated SNA, MAA, or unconjugated Siglec-E-Fc 
(detected with PE-anti-mouse IgG Fc) in conjunction with APC-conjugated anti-CD11c mAb. Data shown are histrograms depicting the binding of 
SNA, MAA and Siglec-E-Fc respectively. (F) Siglec-E-Tlr4 association is increased on Neu1−/− splenocytes, as measured by captured Tlr4 in plates 
coated with Siglec-E-Fc. (G) Neu1 deficiency increases resistance to LPS challenge. Data shown are Kaplan Meier survival curves of mice that 
received the indicated doses of LPS (i.p., n = 5 in all groups). The mice were observed for 2 weeks, though all death occurred within 72 hr. (H) Cytokine 
production in blood measured 16 hr after LPS treatment. Data represent the mean ± SD. All data in this figure are representative of two to three 
independent experiments.
DOI: 10.7554/eLife.04066.006
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Correspondingly, Siglec-E-Fc showed reduced binding to DCs after LPS stimulation, and this effect 
was rescued by incubation with a sialidase inhibitor, indicating that Siglec-E binding to its ligands was 
disrupted by sialidase activity (Figure 4B).
Since we showed Neu1 to be a key regulator of Siglec-E-TLR4 interaction and of the TLR4 function 
in vitro, we sought a genetic model to definitively address the potential role of Neu1 in the host 
response to endotoxemia. However, mice with homozygous deletion of the Neu1 locus develop clinical 
abnormalities reminiscent of early-onset sialidosis in children, including severe nephropathy, progres-
sive edema, splenomegaly, kyphosis and urinary excretion of sialylated oligosaccharides (de Geest 
et al., 2002). To avoid these developmental defects, we produced bone marrow chimeric mice by 
reconstituting WT congenic mice with WT or Neu1−/− bone marrow cells, and compared their survival 
and cytokine responses following LPS challenge. Bone marrow from CD45.2+ Neu1−/− donors was as 
competent as WT bone marrow in reconstituting lethally irradiated CD45.1 hosts (Figure 4C), and the 
major hematopoietic cellular components were not affected by Neu1 deficiency (Figure 4D). Animals 
reconstituted with Neu1−/− bone marrow had increased sialylation and Siglec-E binding to DC (Figure 4E), 
and more specifically, Siglec-E-TLR4 association (Figure 4F).
To test the role for Neu1 in susceptibility to LPS, we challenged chimeric mice with 100–400 μg LPS/
mouse and monitored their survival over a 2 week period. As shown in Figure 4G, 100% of mice recon-
stituted with WT bone marrow cells succumbed to all doses of LPS tested. In contrast, the majority 
of mice reconstituted with Neu1−/− bone marrow were resistant to 100 and 200 μg doses of LPS. 
Corresponding with the increased resistance, the Neu1−/− >WT chimera mice produced significantly 
less IL-6 and TNFα following LPs stimulation (Figure 4H). These data conclusively demonstrate a crit-
ical role for Neu1 in host response to endotoxemia.
A sialidase inhibitor protects mice against endotoxemia
The significant reduction of endotoxemia in mice with Neu1-deficient hematopoietic cells suggests 
that endogenous sialidase may be a valuable therapeutic target. To test this concept, we injected 
450 µg LPS i.p. into C57BL/6 mice. Immediately after LPS injection, the mice were treated with either 
PBS or a mixture of two sialidase inhibitors, Neu5Ac2en and Neu5Gc2en, that we previously found to 
protect mice against polymicrobial sepsis (Chen et al., 2011). As shown in Figure 5A, while 80% of 
the vehicle-treated mice succumbed to LPS challenge, all mice that received the inhibitors survived 
throughout the observation period. Interestingly, the inhibitors had no significant effect on the first 
cytokine storm, but drastically inhibited IL-6 and TNF-α production 24 and 48 hr post LPS administration 
(Figure 5B,C). Of the two inhibitors used, Neu5Gc2en accounted for most, if not all, of the therapeutic 
effect (Figure 5D).
The fact that sialidase inhibitors have no effect on the first major wave of inflammatory cytokines 
suggests that the drug can be used therapeutically. Indeed, as shown in Figure 5E, Neu5Gc2en 
conferred complete protection even when it was administered 6 hr after LPS injection. Furthermore, 
since clinical manifestations are usually caused by a combination of bacteremia and enodoxemia in a 
more chronic manner (Hurley, 1995), we tested the protective effect of NEU1 inhibitor for infection 
with endotoxin-producing Escherichia coli. As shown in Figure 5F, Neu5Gc2en protected mice against 
lethal E. coli (strain 25922) infection.
As shown in Figure 1B,F, TLR4 interacts strongly with both Siglec-E and F. It is therefore of interest 
whether the sialidase inhibitor preserved the Tlr4-Siglec-E and/or Tlr4-Siglec-F interactions. We tested 
whether Neu5Gc2en preserved Tlr4-Siglec interaction using the in vitro capture assay. As shown 
in Figure 5G, LPS treatment reduced both Siglec-E:Tlr4 and Siglec-F:Tlr4 interactions, while treatment 
with Neu5Gc2en preserved both interactions. Functional redundancy of the two Siglecs explains lack 
of strong phenotype of mice with Siglec-E deletion in endotoxemia (data not shown).
Cell surface Neu1 is the therapeutic target of the sialidase inhibitor
As the first step to identify the therapeutic targets of Neu5Gc2en, we compared the inhibitory effect 
of Neu5Ac2en and Neu5Gc2en against Neu1-4. We transfected 293T cells with cDNA encoding 
mouse Neu1-4 and use the lysates of the transfectants as the source of sialidases and determined the 
inhibition of their function by the sialidase inhibitors Neu5Ac2en and Neu5Gc2en. As shown in Figure 6A, 
while both Neu1 and Neu2 were efficiently inhibited by Neu5Ac2en and Neu5Gc2en, Neu3 and Neu4 
are largely resistant. Importantly, while Neu2 was equally sensitive to both inhibitors, Neu1 was 10-fold 
more sensitive to Neu5Gc2en than to Neu5Ac2en. Since Neu5Gc2en but not Neu5Gc2en conferred a 
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therapeutic effect (Figure 5D), we hypothesized that Neu1 is likely the relevant target. To test this 
notion, we compared DC cultured from WT and Neu1−/− bone marrow for their cytokine response to 
LPS in the presence or absence of Neu5Gc2en. As shown in Figure 6B, targeted mutation of Neu1 
reduced production of both IL-6 and TNFα by more than 70%. Importantly, while WT DC responded 
to Neu5Gc2en inhibition, Neu1−/− DC were largely resistant, confirming that Neu5Gc2en inhibits cyto-
kine responses by targeting Neu1.
To ascertain if NEU1 is the therapeutic target of Neu5Gc2en in endotoxic shock, we challenged 
bone marrow chimeric mice with a lethal dose of LPS (200 μg for WT chimera and 400 μg for Neu1−/− 
chimera, see Figure 4G) and determined the effect of Neu5Gc2en, administrated at 6 hr after LPS 
challenge. As shown in Figure 6C,D, Neu5Gc2en was therapeutic only in WT, but not Neu1−/− chimeric 
mice. Therefore, Neu5Gc2en protects mice against endotoxemia by targeting Neu1.
While Neu1 normally resides in the lysosome, it has been shown to translocate to the plasma mem-
brane after LPS stimulation (Liang et al., 2006). To test whether the Neu5Gc2en inhibits cell surface 
or intracellular Neu1, we first incubated either unstimulated or LPS-stimulated D2SC cells with either 
Neu5Gc2en or vehicle control for 1 hr and washed away unbound inhibitor. The cells were then lysed 
to measure sialidase activity. Regardless of LPS stimulation, all sialidase activity was eliminated by 
shRNA silencing of Neu1, which indicated that this assay measured primarily Neu1 activity in the D2SC 
cells (Figure 7A). Upon LPS stimulation, the total Neu1 activity was increased, and all activity was 
inhibited by Neu5Gc2en (Figure 7A). In contrast to LPS-stimulated D2SC, a depot of Neu1 resistant 
to extracellularly-administered Neu5Gc2en was present in the unstimulated D2SC. However, this residual 
sialidase activity was eliminated by adding Neu5Gc2en to the lysates (Figure 7A). Since unstimulated 
Figure 5. Sialidase inhibitors protect mice against endotoxic shock and preserve Siglec-TLR interactions. (A) and (D) Survival analyses of mice that were 
treated with 450 µg/mouse of LPS (i.p., Escherichia coli 0111:B4). The mice received NeuAc2en and/or NeuGc2en (100 µg/mouse/injection) immediately after 
LPS administration and every 24 hr thereafter. (n = 8–10 for a and n = 5–6 mice for (D), 6–8 week old male mice were used). (B) and (C) Sialidase inhibitors 
reduce the levels of IL-6 (B) and TNF-α (C), measured at indicated time after LPS treatment. Data shown are means ± SD. (n = 8–10, 6–8 week old male 
mice). (E) Therapeutic effect of sialidase inhibitors. C57BL/6 mice received 250 µg/mouse of LPS (i.p., E. coli 0111:B4). The mice received NeuGc2en 
(100 µg/mouse/injection) 6 hr after LPS administration and every 24 hr thereafter. (n = 8–10, 6–8 week old male mice). (F) Neu5Gc2en protects mice 
against lethal E. coli (strain 25,922, 107 CFU) infection. (G) Sialidase inhibitor prevents LPS-induced disruption of the Siglec-TLR4 interaction. 1 × 107 
splenocytes were cultured in RPMI supplemented with 10% FBS, stimulated with or without 2 μg/ml LPS in the presence of 100 μg/ml NeuGc2en or 
vehicle for 16 hr, and then the cells were lysed. The lysates were added to wells precoated with Siglece-Fc, Siglecf-Fc or hIgG-fc. The amounts of TLR4 
captured were measured using anti-TLR4 mAb. All data in this figure are representative of two to three independent experiments.
DOI: 10.7554/eLife.04066.007
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DC also have cell surface Neu1 (Figure 3C), we suspect that Neu5Gc2en-sensitive Neu1 resides 
on the plasma membrane, while the Neu5Gc2en-resistant fraction is intracellular. To test this notion, 
we fractionated plasma membrane and cytoplasm from D2SC after the live cells were incubated with 
either vehicle or Neu5Gc2en, and compared their sialidase activities. As shown in Figure 7B, while the 
plasma membrane sialidase activity was significantly reduced, the cytoplasmic sialidase activity was 
unaffected. Since Neu5Gc2en selectively inhibited cell surface Neu1, it is possible to preserve intracel-
lular Neu1 function while targeting cell surface Neu1 with Neu5Gc2en.
Discussion
Siglecs are cellular receptors for sialic acid-decorated biomolecular structures. Consistent with its 
intracellular ITIM- or ITIM-like motifs, engagement of Siglec-G with its natural ligands has been shown 
to inhibit both innate immune responses and adaptive T cell responses (Chen et al., 2009; Bandala-
Sanchez et al., 2013; Toubai et al., 2014).
The function of Siglec 2 (CD22) and Siglec-G in immune tolerance has also been demonstrated 
using both synthetic ligands and mice with deletions of the Cd22 and Siglecg genes (Duong et al., 
2010; Jellusova et al., 2010; Pfrengle et al., 2013). Targeted mutation of Siglecg revealed its critical 
Figure 6. NeuGc2en targets Neu1 to inhibit inflammation and confer protection against endotoxemia. (A) Comparison 
of Neu5Ac2en and Neu5Gc2en for inhibitory activity against mouse Neu1-4. Lysates from 293T cells transiently 
transfected with murine Neu1-4 cDNA were assayed for sialidase activity in the presence of indicated concentrations 
of inhibitors. Data shown are means ± SD of % inhibition of the activity of each sialidase by indicated concentration 
of inhibitors. (B) Neu5Gc2en targets Neu1 to inhibit production of inflammatory cytokine by DC in response to LPS. 
TNFα (upper panel) and IL-6 (lower panel) production by DC cultured from Neu1+/+ or Neu1−/− bone marrow. 
The DC were stimulated with LPS (100 ng/ml) in the presence or absence of indicated doses of Neu5Gc2en. 
Data shown are means ± SD (n = 3) and have been reproduced twice. (C) and (D) Chimeras consisting of either WT 
or Neu1−/− bone marrow were challenged with lethal doses of LPS (200 μg/mouse) for WT (C), and 400 μg/mouse 
for mutant chimeras (D). Sialidase inhibitor was injected at 6 hr after LPS challenge. Data shown are Kaplan–
Meier survival curves. Data are representative of those obtained from two to four independent experiments. 
Statistical significance of survival analysis was determined using log-rank tests, while the pairwise comparison was 
performed with Student's t tests.
DOI: 10.7554/eLife.04066.008
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role for inflammatory cytokine production to tissue injuries (Chen et al., 2009) and type I interferon 
response to RNA viruses (Chen et al., 2013). Likewise, mutation of Siglece has been shown to enhance 
inflammatory cytokine production to bacterial infection (Chang et al., 2014) and neutrophil recruit-
ment to lung (McMillan et al., 2013). A fusion protein consisting of extracellular domain of Siglec-E 
and IgG-Fc (Siglec-E-Fc) is a potent inhibitor of TLR4 response in vitro (Boyd et al., 2009). However, 
the target of Siglec-E-Fc was not identified. Despite these interesting observations, it is unclear how 
pattern recognition by Siglec family members may relate to other prototypic innate pattern recogni-
tion receptors such as TLRs.
By showing a broad physical interaction between Siglecs and TLRs, our data provides a missing link 
between these two PRR families. The biological significance of the interactions is confirmed by the 
broad impact of Siglece mutation on response of DCs to all TLR ligands tested. Although a number of 
intracellular negative regulators have been described to regulate TLR function (Kawai and Akira, 
2010), to our knowledge, Siglecs constitute the first class of cell surface pattern recognition receptors 
that are directly involved in regulation of TLR function.
By virtue of the broad and direct interaction between TLRs and Siglecs, one may envision that 
under steady-state conditions, TLR-induced inflammation may be relatively moderate as TLR func-
tions are either directly (in case of Siglec-E) or indirectly (in case of Siglec-G) restrained by sialoside-
based pattern recognition. In case of tissue injury, a moderate inflammation may be beneficial for 
tissue remodeling and regeneration (Takahashi et al., 2008). Infection can boost inflammation 
through microbial sialidase, as we have recently reported (Chen et al., 2011), or as shown herein, 
by inducing translocation of host Neu1 to the cell surface to disarm the Siglec-mediated negative 
regulation of TLR function.
Since the Neu1 translocation is induced by microbial TLR ligand, a positive feedback is created to 
release the Siglec brake for TLR activation. The molecular mechanism for TLR4-induced Neu1 translo-
cation is largely unclear, although Neu1 translocation during differentiation from monocytes to mac-
rophage occurs by a route used by MHC class II (Liang et al., 2006). Engagement of TLR4 also activates 
cell surface Neu1 activity, perhaps by G protein-coupled receptor and matrix metalloproteinase-
9-dependent mechanisms (Amith et al., 2009; Abdulkhalek et al., 2011). In addition to regulating 
Siglec-TLR interaction, Neu1 has also been shown to induce TLR4 dimerization and thus potentially 
stimulate TLR4 activity (Amith et al., 2010).
Figure 7. Exogenously added Neu5Gc2en inhibits cell surface but not intracellular Neu1. (A) LPS stimulation increased sensitivity of Neu1 to exogenously 
added Neu5Gc2en. D2SC were transduced with lentiviral vectors encoding either scrambled or Neu1 shRNA and incubated with or without 1 µg/ml 
Neu5Gc2en for 30 min. After washing away the inhibitors, the lysates were analyzed for residual sialidase activity. Sialidase activity in the lysates was 
detected with 4-MU-NANA. To confirm that remaining activity is susceptible to Neu5Gc2en, the lysates were also assayed in the presence or absence of 
1 µg/ml Neu5Gc2en. (B) When added to intact cells, Neu5Gc2en inhibits cell surface but not intracellular Neu1. D2SC cells were incubated with 1 μg/ml 
of Neu5Gc2en for 1 hr. The plasma membrane and cytoplasmic membranes were prepared as described (Liu and Fagotto, 2011) and measured for 
sialidase activity. The top panel shows Neu1 activity in cell membrane and cytosolic fractions of the D2SC cells (triplicate data, and mean ± SEM), while 
the lower panel shows commonly used marker proteins to show the purities of the plasma membrane (caveolin) or GAPDH (cytoplasm). Data are representative 
of those obtained from two independent experiments. Pairwise comparison was performed with Student's t tests.
DOI: 10.7554/eLife.04066.009
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It is also of interest to note that TLR-mediated trans-regulation of cellular glycosylation was 
described through genetic screen in Drosophila (Seppo et al., 2003), although the functional 
significance was not clear. The positive feedback described herein suggests a physiological func-
tion of TLR-induced glycosylation switch.
Our data showed that Siglec-E mutation affects the function of both cell surface and endosomal 
TLRs. It is unclear how Siglec-E may affect endosomal TLRs. However, As a member of CD33-like 
Siglecs that are known to be readily endocytosed (Walter et al., 2008), Siglec-E may form physical 
complexes with endosomal TLRs.
The Siglec family of PRR may help the innate immune system to discriminate between infection and 
tissue injury by two distinct mechanisms. First, as represented by Siglec-G/10, which does not directly 
associate with TLR, Siglecs may selective repress inflammation by binding to a DAMPs-associated natural 
ligand, such as CD24, to inhibit host response to DAMPs. Second, as represented by Siglec-E which 
directly associates with TLR, Siglecs may regulate inflammation to endogenous TLR ligands by default. 
By either inducing translocation of intracellular sialidase or by producing microbial sialidases, infection 
can exacerbate inflammatory cytokine production to disrupt direct Siglec-TLR interactions (Figure 8).
The broad impact of Siglecs in the inflammatory response suggests that the interaction with 
TLR may be preserved to reduce inflammation in cases of detrimental inflammation, such as sepsis. 
However, since one Siglec can interact with multiple TLRs, and each TLR with multiple Siglecs, it is 
unlikely that blocking specific Siglecs may significantly impact the susceptibility to endotoxemia. 
In contrast, as sialidases may regulate multiple Siglec-TLR interactions, targeting host sialidase may be 
more effective. Indeed, we showed that inhibition of Neu1 by either gene deletion or sialidase inhib-
itor administration confers a strong protection against endotoxemia. Therefore, Neu1 may serve as a 
new therapeutic target for endotoxic shock.
Sepsis remains a major challenge despite advances in antibiotics, and many sepsis cases are caused 
by gram-negative bacteria (Hurley, 1995; Angus et al., 2001; Seyrantepe et al., 2003; Dombrovskiy 
et al., 2007). We have recently shown bacterial sialidase as a valuable target for polybacterial sepsis 
(Chen et al., 2011). However, most pathogens do not encode sialidase. With the identification of a 
critical function of endogenous sialidase, we can now extend the potential of this strategy to more 
sepsis-causing pathogens. Unlike bacterial and viral sialidases, endogenous sialidases may be easier to 
target as they are both limited in diversity and unlikely to acquire drug resistance through mutation. 
However, since mutation of Neu1 cause sialidosis (Seyrantepe et al., 2003), it is of interest to consider 
how potential side-effects associated with Neu1 inactivation may be avoided. Fortunately, our data 
demonstrate that an effective sialidase inhibitor can confer protection by selectively targeting cell 
Figure 8. Sialoside-based pattern recognition and self-nonself discrimination by the innate immune system. TLR 
signaling is restrained by Siglecs that are either directly (such as Siglec-E) or indirectly through Cd24 (such Siglec-G) 
in the case of tissue injuries. Infections cause a positive feedback in TLR signaling. Infections cause translocation of 
Neu1 to cell surface and/or to production of bacterial/viral sialidases. Both host and cellular to desialylate TLR and/or 
CD24. The Siglecs are dissociated from TLR to allow a more robust inflammation.
DOI: 10.7554/eLife.04066.010
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surface Neu1, perhaps by virtue of poor drug accessibility to the intracellular compartment. Therefore, 
it is feasible to target Neu1 therapeutically without side effects associated with disruption of the intra-
cellular sialidase activity, the known cause of sialidosis.
Taken together, our data establish a missing link between the TLR and Siglec families of pattern 
recognition receptors. The specificity of individual Siglecs allow them to play distinct roles in innate 
immunity, while regulation of the interaction by host sialidase suggest a novel approach for treatment 
of inflammatory diseases, such as sepsis.
Materials and methods
Reagents
Recombinant proteins consisting of human IgG Fc and extracellular domains of human SIGLEC1, 2, 3, 
5, 6, 7, 9, 10, 11, and mouse Siglec1, 2, E, F were purchased from R&D Systems (Minneapolis, MN). 
Recombinant mouse Siglec3-hIgGFc was purchased from Sino Biological, Inc. (Beijing, China) and anti-
mouse TLR4 (MTS510) from Biolegend (San Diego, CA). Anti-human TLR4 and Anti-Siglec-E were from 
R&D. Anti-mouse CD11c, CD11b, CD4, CD8, B220 and Gr1 were purchased from eBioscience (San 
Diego, CA). Anti-Neu1 (H-300) and anti-Neu3 (M-50) antibodies and Horseradish perioxidase conju-
gated anti-mouse, anti-goat or anti-rabbit secondary-step reagents, as well as anti-TLRs antibodies that 
are cross-reactive for mouse and human TLR1 (H-90), TLR2 (A-9), TLR3 (M-300), TLR5 (M-300), TLR6 
(N-18), TLR7 (N-20), TLR8 (H-114), TLR9 (H-100) and TLR10 (V-20) were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA) and biotinylated for studies used in Figure 1A,B. Lipopolysaccharide 
(LPS, from E. coli 0111:B4) was from Sigma. E. coli (strain 25922) was obtained from ATCC (Manassas, 
VA). Neu5Ac2en and Neu5Gc2en were synthesized as described (Li et al., 2008, 2011).
Cell culture and lentiviral infection
D2SC cell line was obtained from Dr Yong-Jun Liu, and maintained in Dulbeco's minimal essential 
medium supplied with10% fetal calf serum and 1% penicillin and streptomycin. The lentiviral vectors 
expressing Neu1 shRNAs or Neu3 shRNA were from Thermo Scientific (San Diego, CA). Puromycin 
was purchased from Sigma. Stable clones were obtained after selection with puromycin (2.5 μg/ml) 
for 3 weeks after infection.
Experimental animal models
All mice were used at 6–8 weeks of age. All animal procedures were approved by the Animal Care and 
Use Committee of University of Michigan and that of Children's National Medical Center.
Siglece−/− mice
Mice with targeted mutations of Siglece were derived from 129/Sv ES cells produced by Mutant 
Mouse Regional Resource Center (MMRRC) at UC Davis (Davis, CA). The mice were backcrossed to 
C57BL/6 for three generations. Bone marrow from Siglece+/+ and Siglece−/− littermates were used to 
prepare DC for the current studies. Since the 129/Sv has a mutation in the Caspase11 gene which is 
involved in the LPS response (Broz et al., 2012), we also typed the genotype of Caspase11 and 
excluded mice homozygous Caspase11 mutation from the current study.
Bone marrow chimeric mice
Bone marrow chimeras were produced as described (Chen et al., 2008), using a total of 5 × 106 bone 
marrow cells from either WT or Neu1−/− mice as donors, and WT mice as recipients.
Quantitative real-time PCR analysis
Neu1-4 and TLRs expression measured by real-time polymerase chain reaction. The primers for human 
TLR were from the TLR-primer set (InvivoGen, version #09H31-MM, Toulouse, France); those for murine 
Neu1-4 were:
 
Neu1 Sense ATGTGACCTTCGACCCTGAG
Neu1 antiSense TCCTTCTGCCAGGATGTACC
Neu2 Sense GCTCTACCTGAAGAAGCAGAAG
Neu2 antiSense GACATGGATTCATGGAGCGGTG
Neu3 Sense TGCGTGTTCAGTCAAGCC
Neu3 antiSense GCAGTAGAGCACAGGGTTAC
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Neu4 Sense TGGTCTGCGGAGCCTGATATTG
Neu4 antiSense AGTAACGCAGGCACACGGTAG
Hprt Sense AGCCTAAGATGAGCGCAAGT
Hprt antiSense TTACTAGGCAGATGGCCACA
 
Samples were run in triplicate, and the relative expression was determined by normalizing expression 
of each target to the endogenous reference, hypoxanthine phosphoribosyltransferase (Hprt) transcripts 
or GAPDH.
Construct of plasmids
To generate a construct expressing recombinant proteins consisting of human IgG Fc and extracellular 
domains of Siglec-G or H, the corresponding cDNA fragment was amplified by PCR and subcloned into 
expression vector pFUSE-hIgG1-Fc (Invivogen). cDNA for Neu1-4 were amplified by RT-PCR and sub-
cloned into expression vector pCDNA6 (Life technologies, Grand Island, NY). All constructs were verified 
by restriction enzyme digestion and DNA sequencing. For purification of Siglec-G-Fc or Siglec-H-Fc, the 
corresponding expression vector was co-transfected with a GFP expression vector into 293 T cells, and 
stable clones were obtained after 2 weeks culture in selection medium containing 2.5 μg/ml puromycin 
and 50 μg/ml Zeocin. The stable clones were amplified and cultured in serum free medium, Siglec-G-Fc 
or Siglec H-Fc was purified with a protein A column from the cell culture supernatants.
Preparation of DC from murine bone marrow
Bone marrow cells were isolated from femurs and incubated in RPMI complete medium supplemented 
with 10% fetal calf serum (Life Technologies) and 10 ng/ml recombinant mouse GM-CSF (Peprotech, 
Coconut Creek, Florida) and 1 ng/ml IL-4 (Peprotech) for 12 days and then stimulated with different 
TLR ligands from the Mouse TLR1-9 Agonist Kit, InvivoGen. Cytokines in the supernatant were 
determined using mouse inflammation CBA kit (552364; BD Biosciences, San Diego, CA).
Flow cytometry
Spleen cells from untreated WT mice, LPS treated WT mice, Neu1 knockout mice or culture cells were 
washed in flow staining buffer (1× PBS, 2% BSA), and incubated for 1 hr on ice with different directly 
conjugated-antibodies in flow staining buffer. The intensity of cell-bound antibodies was analyzed on 
a FACSCanto II cytometer (Becton Dickinson, San Diego, CA). For Siglec-E binding assay, 1 µg of 
SiglecE-Fc incubated with the cells in 100 μl of the flow staining buffer. Unbound fusion proteins 
were washed and then incubated with PE-anti-mouse IgGFc antibody (1:400) for another hour on 
ice. The amounts of cell-bound Siglec-E-Fc was analyzed in Canto II cytometer.
Immunoprecipitation and immunoblotting
D2SC cell lysates were prepared in lysis buffer (20 mM Tris–HCl, 150 mM NaCl, 1% Triton X-100, 
pH 7.6, including protease inhibitors, 1 μg/ml leupeptin, 1 μg/ml aprotinin and 1 mM phenylmethyl-
sulfonyl fluoride), sonicated, centrifuged at 13,000 rpm for 5 min and then diluted in IP buffer (20 mM 
Tris–HCl, 150 mM NaCl, pH 7.6, including the protease inhibitors as described above). Samples were 
pre-cleared with 60 µl of protein A-conjugated agarose beads (Upstate, Lake Placid, NY) for 2 hr at 
4°C or 37°C, and then incubated with corresponding antibodies. Immunoprecipitates were washed 
four times with IP buffer and re-suspended in SDS sample buffer for Western blot analysis. 
Coimmunoprecipitation between Neu1 and TLR4 were carried out after the live cells were crosslinked. 
Briefly, D2SC cell lines were stimulated with 2 μg/ml LPS or vehicle for 16 hr. Live cell suspension were 
incubated with with 1 mM DSP in the reaction buffer (pH7.5, 20 mM HEPES, 0.1 M phosphate, 0.15 M 
NaCl) at room temperature for 30 min and then stopped by adding 20 mM pH 7.5, Tris and incubated 
at room temperature for 15 min prior to lysis.
Siglec-TLR capture assay
96-Well plates were coated with either Siglecs or IgGFc in 50 mM carbonate/bicarbonate buffer, 
pH 9.5, overnight at 4°C. Wells were blocked with ELISA buffer (20 mM Tris–HCl, 2% bovine serum 
albumin, 150 mM NaCl, pH 7.6) for 1 hr. Spleen or THP-1 cell lysates were prepared in the lysis buffer 
(20 mM Tris–HCl, 1% Triton X-100, 150 mM NaCl, PH 7.6), sonicated, centrifuged at 13,000 rpm 
for 5 min and then diluted in ELISA buffer. 100 µl cell lysates (1 µg/µl) were added to the plate and 
incubated for 2 hr. Between incubations (all at 37°C), the plates were washed five times with the ELISA 
buffer. Biotinylated-anti-TLR antibody (0.05 μg/ml) was used to detect bound TLRs. The plate-associated 
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biotinylated proteins were detected by horse-radish perioxidase (HRP)-conjugated streptavidin (1:1000) 
for 1 hr and developed with 100 μl/well p-nitrophenyl phosphate liquid substrate system. Absorbance 
at 450 nm was recorded. In some experiments, cell lysates were replaced with recombinant TLR4 
ectodomain (1 μg/ml, R&D) in order to measure direct interaction between Siglecs and TLR4.
Measurement of inflammatory cytokines
Blood or cell culture supernatants were obtained at indicated times and cytokines in the serum or cell 
culture supernatants were determined using mouse cytokine bead array designed for inflammatory 
cytokines (552364; BD Biosciences).
Neuraminidase activity assay
Sialidase activity was measured using 2′-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid sodium 
salt hydrate (4-MU-NANA) (M8639; Sigma) as the substrate. 293 T cells (4 × 106) were transiently trans-
fected with 10 µg of Neu1-4 expression vectors as described above or empty vector as control. 48 hr 
after transfection, cells were harvested and suspended in 100 µl of lysis buffer (20 mM Tris–HCl, 
1% Triton X-100, 150 mM NaCl, pH 7.6), sonicated and centrifuged at 13,000 rpm for 5 min. For one 
reaction, 5 µl of the supernatant was first mixed with different amounts of sialidase inhibitors and then 
incubated with 4-MU-NANA (final concentration, 15 µM) for 30 min at 37°C in 50 µl reaction buffer 
(50 mM Sodium phosphate, pH 5.0). The reaction was terminated by adding 600 µl stop buffer 
(0.25 M glycine-NaOH, pH 10.4) and then fluorescence intensity was measured with a FLUOstar 
OPTIMA (BMG LABTECH GMBH, Germany) (excitation at 360 nm; emission at 460 nm).
Immunofluorescence
D2SC cells were seeded in the chamber slides and treated with 100 ng/ml LPS for 18 hr and then 
fixed with methanol/acetone (50:50 Vol) for 20 min at −20°C. After washing with PBS, cells were 
blocked by PBS containing 5% bovine serum albumin and stained by rabbit anti-Neu1 polyclonal 
antibody (H-300; Santa Cruz Biotech) for 1 hr at room temperature. After washing with PBS, cells 
were stained by Alexa Fluor 568-conjucated anti-rabbit IgG (Invitrogen, San Diego, CA). Subsequently 
cells were stained by rat anti-TLR4 monoclonal antibody (Sa15-21; BioLegend) and washed and stained 
by Alexa Fluor 488-conjucated anti-rat IgG (Invitrogen). DNA was stained with DAPI. Fluorescence 
images were taken under an Olympus X51 microscope.
Statistical analysis
The differences in cytokine concentrations were analyzed by the Student's t test. The differences 
in survival rates were analyzed by Kaplan-Meier plot and statistical significance determined using a 
log-rank test. *p < 0.05, **p < 0.01, ***p < 0.001.
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